Astellas Pharma (OTCMKTS:ALPMY) Stock Rating Upgraded by Zacks Research

Astellas Pharma (OTCMKTS:ALPMY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Astellas Pharma has an average rating of “Moderate Buy”.

Astellas Pharma Stock Up 1.4%

ALPMY stock opened at $13.35 on Tuesday. Astellas Pharma has a twelve month low of $9.22 and a twelve month high of $17.35. The company has a market cap of $24.16 billion, a PE ratio of 12.43 and a beta of 0.07. The business’s 50-day simple moving average is $14.31 and its 200 day simple moving average is $14.65. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. On average, research analysts anticipate that Astellas Pharma will post 1.34 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).